A Look At TG Therapeutics (TGTX) Valuation After Fresh BRIUMVI Clinical And Formulation Milestones

TG Therapeutics (TGTX) is drawing attention after a cluster of BRIUMVI related updates, including positive Phase 3 ENHANCE data and new subcutaneous and post hoc efficacy results in multiple sclerosis. See our latest analysis for TG Therapeutics. The BRIUMVI news has arrived alongside strong share price momentum, with a 90 day share price return of 54.62% and a year to date share price return of 48.12%. Meanwhile, the 3 year total shareholder return of 57.82% and 5 year total shareholder return of 15.93% highlight how recent gains compare with the longer term. If this kind of clinical news has your attention, it can be worth checking which other healthcare stocks tied to AI and data driven research are moving via the 39 healthcare AI stocks The stock is trading at $43.37, with an implied upside to the average analyst price target of $48 and an intrinsic value estimate suggesting a wider discount. So are investors still underpricing BRIUMVI, or is the market already factoring in future growth? Most Popular Narrative: 2.4% Undervalued Against the last close at $43.37, the most followed narrative pegs TG Therapeutics’ fair value at about $44.43, leaving only a small implied discount but a very detailed earnings and revenue roadmap behind it. The planned launch of subcutaneous (subcu) BRIUMVI is a significant upcoming catalyst, as it could unlock access to 35-40% of the anti-CD20 MS market segment currently dominated by self-administered therapies, greatly increasing BRIUMVI's addressable market and supporting long-term revenue growth. Read the complete narrative. Curious what underpins that near fair value call. The narrative ties together brisk revenue expansion, shifting profit margins, and a richer earnings multiple. The exact mix of assumptions may surprise you. Result: Fair Value of $44.43 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this near fair value story can change quickly if BRIUMVI faces tougher competition or if payers push harder toward lower cost, self administered MS therapies. Find out about the key risks to this TG Therapeutics narrative. Next Steps With sentiment split between upside potential and real concerns, it makes sense to move quickly, review the data for yourself, and weigh the 4 key rewards and 1 important warning sign. Looking for more investment ideas? If you are serious about sharpening your next move, do not stop at one stock. Use focused screens to spot opportunities others might miss. Target potential upside in beaten down corners of the market by scanning 24 elite penny stocks with strong financials before interest rushes in. Zero in on opportunities where quality and price line up by filtering for 46 high quality undervalued stocks that already show solid fundamentals. Prioritize sleep at night holdings by searching for 63 resilient stocks with low risk scores that may better match your risk tolerance. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if TG Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free Analysis